Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Hormone replacement therapies that include continuous progestogen are
associated with less endometrial damage, when used long term, than
sequential oestrogen-progestogen regimens. A prospective study by Wells
and colleagues (p 239) found no cases of endometrial hyperplasia
or malignancy in women taking combined therapy. Continuous daily
progestogen, the authors say, seems to keep the endometrium normal and
correct hyperplasia that may develop during standard sequential
regimens.